Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Differences Between the Obama and Bush White House: A Look Ahead

This article was originally published in RPM Report

Executive Summary

Former HHS general counsel Dan Meron, now a partner at Latham & Watkins, was asked to make predictions on how the Obama Administration would differ from the Bush Administration in a recent speech to the annual meeting of the Food, Drug and Cosmetic Law Section of the New York Bar Association. His remarks were edited for continuity.

You may also be interested in...



Health Care Reform: Plan for Quick Action Dashed By Daschle Withdrawal

The withdrawal of Tom Daschle from consideration as HHS Secretary means there won't be a single focus for health care policy during the upcoming health care reform debate. Can two powerful Democratic legislators and the Obama budget team fill the void?

Health Care and the 2008 Election: Revolution, Reform or Return to Business-as-Usual?

As the presidential race heats up, health care executives say they have many reasons to be excited–and nervous. Boston Consulting Group reviews an industry-wide survey on the implications of the candidates’ health care proposals for the pharma and device industries.

Preparing for Health Care Reform: Why Big Pharma Thinks it Can Avoid Another "Hillarycare"

Should a Democrat take the White House next January, top pharmaceutical executives expect a serious push for health care reform. The prospect of a health care reform debate triggers the specter of a single-payor, government-run system with price controls. But Democrats are singing a surprisingly soothing tune.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel